Gene expression profiling of pediatric acute myelogenous leukemia.

Blood
Mary E RossJames R Downing

Abstract

Contemporary treatment of pediatric acute myeloid leukemia (AML) requires the assignment of patients to specific risk groups. To explore whether expression profiling of leukemic blasts could accurately distinguish between the known risk groups of AML, we analyzed 130 pediatric and 20 adult AML diagnostic bone marrow or peripheral blood samples using the Affymetrix U133A microarray. Class discriminating genes were identified for each of the major prognostic subtypes of pediatric AML, including t(15;17)[PML-RARalpha], t(8;21)[AML1-ETO], inv(16) [CBFbeta-MYH11], MLL chimeric fusion genes, and cases classified as FAB-M7. When subsets of these genes were used in supervised learning algorithms, an overall classification accuracy of more than 93% was achieved. Moreover, we were able to use the expression signatures generated from the pediatric samples to accurately classify adult de novo AMLs with the same genetic lesions. The class discriminating genes also provided novel insights into the molecular pathobiology of these leukemias. Finally, using a combined pediatric data set of 130 AMLs and 137 acute lymphoblastic leukemias, we identified an expression signature for cases with MLL chimeric fusion genes irrespective of lineage. Surpr...Continue Reading

References

Jan 1, 1992·Leukemia & Lymphoma·A K Burnett
Jul 1, 1991·British Journal of Haematology·J M BennettC Sultan
Mar 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·M AlcalayF Lo Coco
May 26, 1991·The New England Journal of Medicine·R P WarrellA Jakubowski
Jul 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D KalwinskyG V Dahl
Jun 21, 1994·Proceedings of the National Academy of Sciences of the United States of America·S A SchichmanC M Croce
Apr 16, 1998·Proceedings of the National Academy of Sciences of the United States of America·M P StroutM A Caligiuri
Sep 30, 1999·The New England Journal of Medicine·B LöwenbergA Burnett
Feb 7, 2001·Proceedings of the National Academy of Sciences of the United States of America·K VirtanevaR Krahe
Apr 20, 2001·Proceedings of the National Academy of Sciences of the United States of America·V G TusherG Chu
Jun 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R A KranceR C Ribeiro
Dec 4, 2001·Nature Genetics·Scott A ArmstrongStanley J Korsmeyer
Apr 17, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maria E Suarez-AlmazorEduardo Bruera
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey E RubnitzFrederick G Behm
Jul 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Claudia SchochTorsten Haferlach
Jul 19, 2002·Cancer Cell·D Gary Gilliland, Martin S Tallman
Oct 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kristine R CrewsRaul C Ribeiro
Nov 6, 2002·Proceedings of the National Academy of Sciences of the United States of America·Zhijian QianMichelle M Le Beau
Dec 25, 2002·Cancer Cell·James R Downing, Kevin M Shannon
Mar 14, 2003·Bone·S KobayashiK Takaoka

❮ Previous
Next ❯

Citations

Nov 12, 2010·European Journal of Clinical Pharmacology·Roberta RussoUNKNOWN TEDDY European Network of Excellence
May 29, 2008·Current Treatment Options in Oncology·Jeffrey E Rubnitz
Jun 1, 2006·Current Hematologic Malignancy Reports·Kenneth I Mills, Amanda F Gilkes
Aug 11, 2005·Current Oncology Reports·Joseph M Scandura
Aug 23, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·M Dolores DelgadoJavier León
Jan 29, 2008·International Journal of Hematology·Yali Dou, Jay L Hess
May 11, 2010·International Journal of Hematology·Tim C P Somervaille, Michael L Cleary
Jul 25, 2013·Journal of Medicinal Chemistry·Justin L Anglin, Yongcheng Song
Mar 6, 2009·Leukemia·K Stegmaier
Mar 27, 2009·Leukemia·T Neff, S A Armstrong
Sep 24, 2010·Leukemia·B V BalgobindM M van den Heuvel-Eibrink
Mar 30, 2011·Leukemia·K Theilgaard-MönchL Bullinger
May 14, 2011·Leukemia·B V BalgobindM M Van den Heuvel-Eibrink
Mar 5, 2013·Leukemia·N R GrieselhuberT J Ley
Jul 25, 2006·Nature·Andrei V KrivtsovScott A Armstrong
Feb 24, 2006·Nature Reviews. Cancer·Meyling H Cheok, William E Evans
Dec 14, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ivo P Touw, Stefan J Erkeland
Oct 4, 2008·Proceedings of the National Academy of Sciences of the United States of America·Zejuan LiJianjun Chen
Nov 10, 2010·The Journal of Experimental Medicine·Letetia JonesScott C Kogan
May 29, 2009·Briefings in Functional Genomics & Proteomics·Ulrike BacherTorsten Haferlach
Oct 6, 2005·Bioinformatics·Stan Pounds, Cheng Cheng
Jun 17, 2006·Bioinformatics·Stan Pounds, Cheng Cheng
Oct 4, 2005·The Cancer Journal·Charles G MullighanJames R Downing
Dec 17, 2005·Current Opinion in Oncology·Tomohiko Taki, Masafumi Taniwaki
Dec 18, 2004·Current Opinion in Hematology·Guido MarcucciClara D Bloomfield
Oct 9, 2008·Current Opinion in Oncology·Krzysztof MrózekClara D Bloomfield
May 27, 2009·Current Opinion in Hematology·Krzysztof MrózekGuido Marcucci

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.